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Rapid determination of salbutamol in
pharmaceutical preparations by chiral capillary
electrophoresis
A fast and simple method of chiral capillary electrophoresis (CE) has been applied to
the analysis of salbutamol in different pharmaceutical preparations. Using of a 25 mM
acetate buffer (pH 5.0), containing 13.1 mg/mL carboxymethyl--cyclodextrin (CM--
CD), an applied voltage of 20 kV and a temperature of 25C, the enantiomers of salbu-
tamol could be separated in about 2 min. Three different pharmaceutical preparations
(two syrups, one oral solution, and two kind of tablets) containing a racemate of salbu-
tamol were injected directly in the CE system, following dilution in dimethyl sulfoxide
(DMSO). Appreciable differences in the retention times were observed for salbutamol
enantiomers in the different formulations studied, which were attributed to the effect of
the matrix components on the electrophoretic mobility. The standard addition method
was used for the calibration due to the existence of matrix interferences. Finally, the
stability of the enantiomers of salbutamol in the oral solution was studied calculating
the enantiomeric ratio values when the solution was injected immediately after being
opened in the first case and after being opened and stored in the fridge for two months
in the second case.
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1 Introduction
Salbutamol is a 2-adrenoceptor agonist clinically used
as bronchodilator for the treatment of patients with
asthma, bronchitis, emphysema and, in general, breath-
ing diseases with bronchoconstriction [1]. The pharmaco-
logical action of salbutamol resides in the R-()-enantio-
mer, which moreover was found to undergo a faster me-
tabolism in men than the S-()-enantiomer [2]. However,
no information is currently available on the toxicity of inac-
tive S-()-enantiomer and salbutamol is still commercial-
ized and administrated as a racemate [3].
Capillary electrophoresis (CE) is an effective tool for the
resolution of enantiomers, which is accomplished by
supplying the background electrolyte with a chiral selec-
tor capable of discriminating between the enantiomers
concerned. In fact, chiral CE has been the subject of
much attention and has been applied with success to
the enantiomeric separation of different chiral com-
pounds during the last decade [4, 5]. The chiral selectors
used for this purpose include cyclodextrins (CDs) and
derivatives, chiral crown ethers, noncyclic oligosacchar-
ides and polysaccharides, macrocyclic antibiotics, pro-
teins and peptides, metal complexes, and chiral surfac-
tants [4, 6–10].
The validation of chiral methods of analysis is of obvious
importance in pharmaceutical science for determining
enantiomeric purity of products, to analyze drugs formu-
lations or to perfom formulation stability studies as it is
shown by the great number of works published on this
subject [5, 6, 11–18]. In the case of the quantitation of
chiral bronchodilators by CE, the developed methods
used -CD derivatives as chiral selectors. Thus, Esquisa-
bel and co-workers [16] obtained the chiral separation of
salbutamol using 2,6-di-O-methyl--CD as chiral selector
in 14 min approximately. This chiral method was applied
to the study of salbutamol enantiomer release frommatrix
tablets that contained the racemic drug and a chiral exci-
pient as hydroxypropylmethylcellulose. No enantioselec-
tive release of the salbutamol from these matrices was
observed. The quantitative determination of salbutamol,
clenbuterol, and tulobuterol enantiomers from a spiked
sample by CE using sulfated -CD as chiral selector has
been performed by Vela and co-workers in about 20 min
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[17]. Finally, a fast enantiomeric separation, in about
2 min, of salbutamol using a neutral -CD derivative (per-
methylated -CD) or a negatively charged -CD derivative
(carboxymethyl--CD) as chiral selector was performed
recently by our research team [18].
The main objective of this work was the application of the
fast and simple chiral CE method developed by our re-
search team for the chiral separation of salbutamol [18]
to the determination of this compound in different phar-
maceutical preparations where it was used as a race-
mate. Furthermore, since there is no information concern-
ing the unstability of one enantiomer of salbutamol with
respect to the other one in pharmaceutical formulations,
the evaluation of the stability of these enantiomers in an
oral solution was also performed.
2 Materials and methods
2.1 Chemicals and samples
All reagents were of analytical grade. Dimethyl sulfoxide
(DMSO), and sodium hydroxide were supplied from
Merck (Darmstadt, Germany); hydrochloric acid was pur-
chased from Panreac (Barcelona, Spain); CM--CD
(degree of substitution 3) was obtained from Cyclolab
(Budapest, Hungary). Water used to prepare solutions
was purified through a Milli-Q system fromMillipore (Bed-
ford, MA, USA). All solutions were filtered through 45 m
pore size disposable nylon filters from Scientific
Resources (Eatontown, NJ, USA). Salbutamol was pur-
chased from Sigma (St. Louis, MO, USA). The structure
of the enantiomers of this basic drug is shown in Fig. 1.
Different pharmaceutical preparations containing salbu-
tamol sulfate were acquired in pharmacy shops at Alcalá
de Henares (Madrid, Spain). Table 1 shows the composi-
tion of the different pharmaceutical preparations studied
in this work.
Figure 1. Structure of the enantiomers of salbutamol.
Table 1. Composition of the different pharmaceutical
preparations studied in this work
Pharmaceutical
preparation Composition
Syrup (A) Salbutamol sulfate, sodium saccharine and exci-
pients (sodium citrate, citric acid monohydrate,
hydroxypropylmethylcellulose, sodium benzoate,
orange flavor, sodium chloride, and purified
water)
Syrup (B) Salbutamol sulfate and excipients (sodium ben-
zoate, hypromelose, sodium saccharine, citric
acid, sodium citrate, orange flavor, and purified
water)
Oral solution (C) Salbutamol sulfate and excipients (sodium ben-
zoate, citric acid monohydrate, sodium sac-
charine, sodium citrate, sodium chloride, aroma
of raspberry, and water)
Tablet (D) Salbutamol sulfate and excipients (corn starch,
polyvinylpyrrolidone, cellulose, sodium starch
caboxymethylated, silicium dioxide, talc,
magnesium estearate)
Tablet (E) Salbutamol sulfate and excipients (sodium chloride,
povidone, sodium croscarmellosa, silicagel,
magnesium estearate, cellulose acetate,
methylhydroxypropylcellulose, titanium dioxide,
hydroxypropylcellulose, lacas rubber, industrial
methylated spirit, 2-etoxyiethanol, n-butyl alco-
hol, aluminium laca of lipstick, and polydime-
thylsiloxano)
2.2 Apparatus
An HP3D CE system (Hewlett-Packard, Waldbronn, Ger-
many) equipped with an on-column diode array detector
(DAD) and an HP 3D-CE Chemstation software was used.
An uncoated fused-silica capillary from Composite Metal
Services (Worcester, England) with 50 m inner diameter
(ID) and 375 m outer diameter (OD) with an effective
length of 25 cm (33.5 cm total length) was employed.
Capillary temperature was set to 25C and UV detection
was performed at 230 nm. Separation voltage was 20 kV.
Electrolytic solutions were degassed in an ultrasonic bath
KM from Raypa (Barcelona, Spain). A 654 pH meter from
Metrohm (Herisau, Switzerland) was employed to adjust
the pH of the separation buffer.
2.3 Procedure
Electrolytic solutions were prepared weighing and dis-
solving the appropriate amount of buffer and CM--CD
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Figure 2. Separation of salbutamol enantiomers in a
standard solution (0.045 mg/mL) and in dilutions of the
five pharmaceutical preparations studied in this work
(0.045 mg/mL in salbutamol) using the chiral CE method.
Experimental conditions: 25 mM acetate buffer (pH 5) with
13.1 mg/mL CM--CD; temperature, 25C; applied volt-
age, 20 kV; UV detection at 230 nm; injection by pressure,
30 mbar for 2 s sample followed by 30 mbar for 2 s buffer;
50 m ID, 375 mOD capillary of 33.5 cm length (25 cm to
the detector).
adjusting the pH to the desired value with a 1 M hydro-
chloric acid solution and 0.1 M sodium hydroxide. Stan-
dard solutions of salbutamol used for the calibration by
the external standard method were prepared by diluting
with DMSO a stock solution of 10 mg/mL of salbutamol
in DMSO to obtain final concentrations comprised from
0.005 to 0.120 mg/mL (0.005, 0.010, 0.020, 0.030, 0.045,
0.060, 0.080, 0.100, and 0.120 mg/mL). The determina-
tion of the salbutamol content in the different pharmaceu-
tical preparations (two syrups, an oral solution, and two
tablets) required a dilution of each formulation in a final
volume of DMSO to achieve a final concentration of
0.015 mg/mL in salbutamol. For the calibration by the
standard additions method, three increasing concen-
trations of salbutamol standard (0.010, 0.030, and
0.060 mg/mL) were added to a solution of the pharma-
ceutical preparation with a concentration of 0.015 mg/
mL of salbutamol. The four resulting solutions were di-
rectly injected in the electrophoretic system. Neverthe-
less, in the case of the tablets it was necessary to include
a centrifugation step to separate the insoluble excipients
from the solution before the injection of the solution in the
CE system. Between injections, the capillary was washed
with 0.1 M sodium hydroxide (10 bar for 0.2 min), followed
by the running buffer (10 bar for 0.4 min). The injection
was made by pressure: 30 mbar for 2 s of sample fol-
lowed by 30 mbar for 2 s of separation buffer.
2.4 Data treatment
All the experimental data were manipulated using Excel
7.0 from Microsoft Office software [19]. Regression analy-
sis, analysis of variance (ANOVA) and comparison of
regression lines for significantly different slopes and inter-
cepts were made using Statgraphics Plus software [20].
3 Results and discussion
3.1 Separation of the enantiomers of
salbutamol in different pharmaceutical
preparations
In a previous work it was reported that the fast enantio-
meric separation of salbutamol, in about 2 min is possi-
ble, using 25 mM acetate buffer (pH 5) containing
13.1 mg/mL CM--CD at a temperature of 25C and an
applied voltage of 20 kV in a capillary of 25 cm of effective
length [18]. These conditions have been applied in this
work to the fast chiral analysis of salbutamol in different
pharmaceutical preparations: two syrups, an oral solu-
tion, and two kind of tablets. Figure 2 shows the electro-
pherograms corresponding to a standard solution of sal-
butamol (0.045 mg/mL) and to five dilutions in DMSO
of the different pharmaceutical preparations studied
containing 0.045 mg/mL of salbutamol sulfate. It was
observed that a mixture of the two enantiomers of salbu-
tamol was detected in all cases and no interfering peaks
were observed. In addition, a similar enantiomeric resolu-
tion for the salbutamol standard and the salbutamol con-
tained in the different pharmaceutical preparations was
observed. However, an increase in the migration times of
the enantiomers of salbutamol detected in some of the
different pharmaceutical preparations was observed with
respect to the migration times of the enantiomers of the
salbutamol standard. This result could be attributed to
the effect of matrix components on the electroosmotic
flow (EOF). According to Table 1 both syrups have a simi-
lar composition, being the difference that syrup (A) con-
tain hydroxypropylmethylcellulose and sodium chloride
instead of the hypromelose contained in syrup (B).
Furthermore, the migration times observed for the salbu-
tamol enantiomers of the oral solution are more similar to
the standard solution than those of the syrups, probably
due to the absence of compounds such as hydroxypro-
pylmethylcellulose or hypromelose which can interact
with the inner wall of the capillary when they are injected
in the CE system [21]. On the other hand, although both
kind of tablets studied have a more complex composition
than the syrups or the oral solution studied, migration
times of the enantiomers of salbutamol in these pharma-
ceutical preparations are similar to the migration times of
Electrophoresis 2003, 24, 2680–2686 Determination of salbutamol by chiral CE 2683
the enantiomers of the salbutamol standard and similar
between them, although their composition is also very dif-
ferent. These results could be explained taking into
account the insolubility observed for some excipients
when these tablets were dissolved in DMSO and which
were separated from the solutions injected in the CE sys-
tem by centrifugation. After these results, we checked if
the chiral CE method was useful for the determination of
the salbutamol content in the different pharmaceutical
preparations considered.
3.2 Quantitation of salbutamol in
pharmaceutical preparations
The quantitation of salbutamol by the chiral CE method
was performed in different pharmaceutical preparations:
two syrups, an oral solution, and two kind of tablets. For
the calibration, corrected total peak areas, calculated as
the addition of the corrected areas corresponding to the
first and the second migrating enantiomers were used
(the corrected area for each enantiomer was obtained by
dividing the area of each electrophoretic peak by its cor-
responding migration time). Although the use of corrected
areas in CE is frequent [22], in this case it was totally
necessary in order to increase reproducibility of calibra-
tion data and also to compensate fluctuations in electro-
phoretic conditions due mainly to the compositions of the
different samples injected and also due to the pH of the
separation buffer (pH 5.0 is a critical value where small
variations of pH values produce big differences in the
electrophoretic mobility) [23].
Solutions of salbutamol standard with concentrations
ranging from 0.005 to 0.400 mg/mL were injected by
triplicate in order to determine the linear concentration
range. It was observed a linear relationship between the
total corrected area and the concentration of salbutamol
in the concentration range between 0.005 and 0.120 mg/
mL. Therefore, solutions of salbutamol standard com-
prised from 0.005 to 0.120 mg/mL were prepared and
injected by triplicate during three different days in the CE
system in order to validate the calibration curve obtained
by plotting corrected total peak area versus concentra-
tion. The equation obtained when the average of the cor-
rected total peak area for the three lines considered ver-
sus the concentration was plotted is y = 0.18710.0362x
being the standard error associated to the intercept
0.0289, to the slope 0.0004, and to the calibration curve
0.0515. The ANOVA of the average of the three calibration
lines considered revealed that the lack of fit was always
statistically smaller than the pure error, which confirmed
that a straight line was a suitable model in the concentra-
tion range employed. In addition, a correlation coefficient
equal to 0.9995 indicated a relatively strong relationship
between the variables. On the other hand, the sensitivity
of this chiral CE method, corresponding to the slope of
the calibration line, was 0.0362 mLg1 (0.0362103
mLmg1).
The slope and the standard error of the calibration curve
were used to calculate the limit of detection (LOD) and the
limit of quantitation (LOQ). LOD and LOQ were defined as
the analyte concentrations given signals exceeding that
of the intercept by 3 and 10 times, respectively, the stan-
dard error of the calibration curve [24]. The LOD calcu-
lated for salbutamol was about 4 g/mL and the LOQ
was about 14 g/mL.
In order to evaluate the precision of the CE method (see
Table 2), repeatability and reproducibility were studied.
The repeatability in migration time and peak area of the
enantiomers and in the corrected total peak area, was
determined (as RSD) for ten consecutive injections of a
dilution in DMSO of each pharmaceutical preparation
with a final concentration of 0.045 mg/mL in salbutamol.
RSD was less than 5.0% for the migration times of the
enantiomers, less than 5.4% for peak area of the enantio-
mers, and less than 4.8% for corrected total peak area.
On the other hand, reproducibility in peak area and migra-
tion time of the enantiomers and in the corrected total
peak area was measured as the RSD obtained in four dif-
ferent days (injections by triplicate) for sample dilutions of
0.045 mg/mL in salbutamol. As it can be observed in
Table 2, the RSD values obtained were less than 5.5%
for the migration times of the enantiomers, less than
6.5% for the peak area of the enantiomers, and for the
corrected total peak area RSD was less than 6.0%. It
should be emphasized that RSD values for the corrected
total peak area are lower than those obtained for the peak
area, that is, the precision obtained for the corrected total
peak areas is better than those obtained with noncor-
rected peak areas, therefore, corrected peak areas were
used for the calibration.
Prior to the quantitative analysis, the presence or
absence of matrix interferences was studied. Then, the
slopes of the regression lines obtained by the external
standard method and the standard addition method,
which was applied to the different pharmaceutical prep-
arations, were compared. Table 3 shows the calibration
lines obtained for the variation of the corrected total
peak area as a function of the concentration of salbuta-
mol standard by the external standard method and as a
function of the added concentration of salbutamol to the
sample by the standard addition method. In addition,
each calibration line was obtained as the average of three
calibration lines obtained in three different days and each
one validated by ANOVA. The comparison of these two
regression lines obtained as explained above for each
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Table 2. Precision in peak areas and migration times for salbutamol enantiomers and in corrected total peak area for
salbutamol in five different pharmaceutical preparations by the CE methoda)
Precision Pharmaceutical
preparation
Csb) t1 (RSD) t2 (RSD) A1 (RSD) A2 (RSD) At (RSD)
Syrup (A) 0.045 2.62 (3.06) 2.69 (3.13) 1.40 (3.24) 1.38 (3.50) 1.05 (3.39)
Syrup (B) 0.045 2.64 (4.97) 2.71 (4.28) 1.17 (3.78) 1.16 (3.79) 0.87 (2.41)
Repeatabilityc) Oral solution (C) 0.045 2.13 (1.48) 2.18 (1.51) 1.24 (3.49) 1.17 (3.76) 1.12 (4.76)
Tablet (D) 0.045 2.02 (2.82) 2.06 (2.86) 0.91 (5.43) 0.91 (4.90) 0.89 (3.73)
Tablet (E) 0.045 1.92 (1.74) 1.97 (1.77) 1.00 (3.58) 1.01 (4.12) 1.03 (3.10)
Syrup (A) 0.045 2.48 (3.87) 2.54 (3.94) 1.33 (4.13) 1.30 (5.99) 1.05 (4.76)
Syrup (B) 0.045 2.60 (4.42) 2.67 (4.48) 1.25 (6.49) 1.20 (6.16) 0.93 (3.63)
Reproducibilityd) Oral solution (C) 0.045 2.14 (1.65) 2.18 (1.52) 1.17 (6.19) 1.20 (4.01) 1.10 (6.00)
Tablet (D) 0.045 1.99 (5.45) 2.02 (5.17) 0.93 (4.46) 0.93 (5.67) 0.93 (4.83)
Tablet (E) 0.045 1.89 (2.98) 1.94 (3.35) 0.95 (4.37) 0.94 (4.79) 0.99 (3.88)
t1 and t2 are the migration times corresponding to the first and the second migrating enantiomers, respectively; A1 and A2
are the peak areas for the first and the second migrating enantiomers, respectively; At is the corrected total peak area ((A1/
t1)(A2/t2)) and the RSD value was calculated with the uncertainty of this mathematic operation [21].
a) Experimental conditions specified in Section 2.3
b) Concentration of salbutamol in a solution prepared by dilution of the commercial preparation (mg/mL)
c) RSD values determined for ten consecutive injections
d) RSD values determined for four different days (each injection was made by triplicate)
Table 3. Comparison of the calibration linesa) obtained by
the external standard method and the standard








Syrup (A) y = 0.18710.0362x
(n = 9, r = 0.9995)
y = 0.73560.0420x
(n = 4, r = 0.9997)
Syrup (B) y = 0.18710.0362x
(n = 9, r = 0.9995)
y = 0.76060.0497x
(n = 4, r = 0.9991)
Oral solution (C) y = 0.18710.0362x
(n = 9, r = 0.9995)
y = 0.70990.0473x
(n = 4, r = 0.9999)
Tablet (D) y = 0.18710.0362x
(n = 9, r = 0.9995)
y = 0.69130.0404x
(n = 4, r = 0.9999)
Tablet (E) y = 0.18710.0362x
(n = 9, r = 0.9995)
y = 0.68330.0417x
(n = 4, r = 0.9995)
a) Calibration lines obtained as the average of three cali-
bration curves obtained in three different days (n, num-
ber of points considered for the calibration curve; r,
correlation coefficient)
b) Concentration range for the salbutamol standard:
0.005–0.120 mg/mL
c) Concentration range for the salbutamol standard
added to the pharmaceutical preparations (dilution
containing 0.015 mg/mL of salbutamol sulfate): 0–
0.06 mg/mL
calibration method and for each pharmaceutical prepara-
tion revealed that statistically significant differences
(P0.05) among the slopes were observed for all the
pharmaceutical preparations studied. Then, the presence
of matrix interferences was detected being necessary to
use the standard addition method for the quantitation of
salbutamol.
The salbutamol content in the different pharmaceutical
preparations studied was determined from a standard
addition line obtained as average of three calibration lines
obtained in three different days and validated by ANOVA
for each pharmaceutical preparation. Table 4 groups the
salbutamol content determined by the chiral CE method
and the salbutamol content calculated taking into
account the salbutamol content decleared in the label of
the product and the dilution in DMSO. Results show that
differences in both values obtained for the syrup (B) and
the oral solution (C) were 2 and 0%, respectively, whereas
for the other three pharmaceutical preparations studied
(syrup (A) and tablets (D) and (E)) these differences were
about 17, 14, and 9%, respectively.
Finally, as the interconversion of enantiomers of a chiral
compound can occur with time [11] and their stability
can be different, it seems interesting to test the change
in the proportion of the enantiomers in stored pharmaceu-
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Table 4. Quantitative analysis of salbutamol in different







mol content in phar-
maceutical prepara-
tion (mg/mL)c)
17.5103 Syrup (A) 15.0103
15.3103 Syrup (B) 15.0103
15.0103 Oral solution (C) 15.0103
17.1103 Tablet (D) 15.0103
16.4103 Tablet (E) 15.0103
a) Experimental conditions specified in Section 2.2
b) Concentration of salbutamol determined by the chiral
CE method
c) Concentration of salbutamol obtained by dilution of the
pharmaceutical preparations considering the salbuta-
mol content indicated in the label of each preparation
tical preparations with a rapid and simple method as used
in this work. The oral solution (C) studied in this work is
prepared by the patient from a powder by dissolving it in
water and storing it in a fridge for consumption to a max-
imum of ten days. The chiral method was applied to study
the stability of the salbutamol enantiomes in this oral so-
lution. In this case, the enantiomeric ratio values for the
oral solution (C) were calculated in order to study if there
was variation in the proportion of the enantiomers of sal-
butamol when the oral solution was injected after being
opened and after being opened and stored in the fridge
for two months. The enantiomeric ratio was calculated
as the corrected area of the second migrating enantiomer
divided by the corrected area of the first migrating enan-
tiomer. An enantiomeric ratio value of 0.92 was obtained
when dilutions in DMSO of the oral solution (C) containing
0.040 mg/mL in salbutamol was opened and immediately
injected in the CE system, and a value of 0.98 was
obtained when dilutions were analyzed after the formula-
tion was opened and stored for two months. Since the
differences between both values of enantiomeric ratio
can be considered within the experimental error, the
results indicated that the racemate has been remained
after the oral solution (C) was opened and stored during
a long time.
4 Concluding remarks
The application of a fast and simple chiral CE method
based on the use of a 25 mM acetate buffer at pH 5 with
13.1 mg/mL CM--CD at 25C and 20 kV as the separa-
tion voltage for the quantitation of salbutamol in different
pharmaceutical preparations (two syrups, an oral solu-
tion, and two kinds of tablets) containing a racemate of
salbutamol was performed in this work. Although differ-
ences in the migration times were observed for the differ-
ent formulations studied, which were attributed to the
influence of their different composition on the electropho-
retic mobility, the use of corrected total peak area enabled
to compensate the fluctuations in the electrophoretic
conditions. The chiral CE method was characterized by a
linear concentration range from 0.005 to 0.120 mg/mL of
salbutamol, LOD of salbutamol about 4 g/mL, and
acceptable values of precision (repeatability and repro-
ducibility) in terms of migration time, peak area, and cor-
rected total peak area. For the quantitation of salbutamol
in the different pharmaceutical preparations studied the
standard additions method was used for the calibration
due to the existence of matrix interferences for a 95%
confidence level. Finally, the stability of the enantiomers
in the oral solution was studied calculating the enantio-
meric ratio values obtained when it was injected after
being opened and after being opened and stored in the
fridge for two months obtaining no significant differences.
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